Potential Problem
An adult transgendered person was referred for dual energy x-ray absorptiometry (DXA). At the time there was no guidance for technologists faced with entering either the patient's birth sex or transgender sex into the instrument's database. Technologists have indicated a need for direction on this practical matter.
Discussion
As yet there is no definitive answer to this question. Each facility has to make decisions based on local issues. Our purpose is set out some of the points to be considered, pending more definitive guidance. Transgendered persons are those whose gender identity is different from their natal sex, which is the sex to which they were assigned at birth. Gender identity is defined as one's sense of self as being either male, female, or of indeterminate sex.
Social Considerations
Many health care professionals have not received formal training in dealing with transgendered patients and may not be comfortable in interacting with and providing care for them. Helpful information to assist physicians is available in publications from British Columbia [1] and the University of California [2] . In the broader social context it is worth noting that the Government of Canada has recently made it easier for a person to amend his or her sex designation on citizenship and passport applications to conform with the person's wishes. Although it has been recommended that primary care medical clinics have 1 category for gender identity and another for sex assigned at birth on the patient record, DXA data entry equates birth sex with gender.
Biomedical Considerations
There is a broad spectrum of transgendered persons, not all of whom choose to become transsexual by transitioning physically to the opposite sex. Therefore many transgendered individuals, from a biological perspective, conform to their natal sex. Of those who have chosen transition, some may be either be taking or may have taken sex hormones surreptitiously, whereas others may be undergoing or may have completed medically supervised hormonal and surgical therapy, which might include male orchiectomy or female oophorectomy. Because of the complex interactions between the sex hormones and bone metabolism, both in the achievement of peak bone mass leading up to skeletal maturity, and then in the subsequent loss of bone with aging, the risk of developing osteoporosis varies widely among transgendered persons. With regard to changes in bone density (BD) during cross-sex hormone therapy, it has generally been reported that male-to-female transgendered individuals receiving androgen blockade and estrogen therapy demonstrate an increase in BD [3e5]. Female-to-male persons receiving testosterone have been reported to either maintain or experience a small increase in BD [5] .
The Endocrine Society recommends that both male-tofemale and female-to-male transgendered persons on cross-hormone therapy be considered for BD testing at baseline if clinical risk factors for osteoporotic fractures are present. In individuals at low risk, screening for osteoporosis should be conducted at 60 years of age and in those who are not compliant with hormone therapy [6] . There are 3 main reasons to perform central DXA: 1) diagnosing osteoporosis; 2) determining fracture risk (50 years of age or older); and 3) monitoring response to treatment [7] . Of these indications, only the monitoring of treatment response (ie, determining change in BD over time) is sex or gender neutral. The subject is being compared with him-or herself and any observed change in BD has the same statistical relevance as if the person's sex had been maintained between serial scans.
However the scanner software determines the subject's standard scores (t scores and z scores) based on the sex entered by the technologist. For any given BD measurement, the corresponding standard score will be different for men and women because their reference population databases differ. There are as yet no specific reference databases for transgendered persons. The t score is used to diagnose osteoporosis by determining diagnostic category as defined by the World Health Organization. It is also a key measurement used in the estimation of fracture risk in the widely used FRAX (Fracture Risk Assessment Tool, World Health Organization, Geneva, Switzerland) fracture risk prediction tool, as well as in other such tools as Canadian Association of Radiologists and Osteoporosis Canada (CAROC) system, Foundation for Osteoporosis Research and Education Fracture Risk Calculator (FORE FRC), and the Garvan Fracture Risk Prevention Tool, all of which require that either male or female sex be entered into the calculator [8] . It follows that both parameters (ie, diagnostic category and estimated fracture risk) might not accurately reflect the bone health of individuals whose sex/ gender identity as recognized by the scanner differs from their actual biological sex. A similar dilemma exists in interpreting the laboratory results of transgendered persons on hormonal therapy [9] .
It is probable that most technologists and physicians performing and interpreting DXA scans will not be fully aware of the treatment protocols of the transgendered patients referred to them for assessment. The densitometrist's report can confidently indicate serial changes in BD irrespective of the recorded sex of the patient, but the assignment of a diagnostic category and estimation of 10-year fracture risk are problematic because our normative databases assume that the individual conforms to his or her natal sex.
A solution for the DXA technologist might be to process each transgendered patient twice, the first time based on the sex declared on the patient questionnaire, and the second time based on the opposite sex. This will provide 2 sets of t scores, 1 for each sex. The reporting physician can then decide how to best interpret and report on the data. For example, diagnostic category and fracture risk could be calculated twice using the standard male and female reference databases. Both reports could be issued to the referring clinician, who is likely the individual best positioned to determine if the transgendered person is biologically male or female, and to assess the clinical implications of the DXA results. It has been suggested that in some individuals, the clinician may wish to assign a fracture risk that is intermediate between the biological male and female values [10] . However, we recognize the disadvantages of such an approach, both in terms of added time and the potential for creating confusion. Clearly, individual facilities will need to determine the most appropriate policy for each to adopt.
Suggestion
Until expert guidelines are developed, facilities that deal regularly with transgendered patients may wish to consider the following policy: When assessing a declared transgendered person for a DXA scan the technologist should follow current social convention and respect the patient's chosen gender identity by entering the sex declared by the patient. After the scan has been completed, the initial printout will reflect this declared identity. The data can then be reprocessed after the technologist has changed the recorded sex, leading to a second printout. Both documents are made available to the physician reporting the scan, who may wish to consider issuing 2 reports for the patient, assigning diagnostic category and fracture risk for both a female and a male individual. This is a policy decision that will need to be made locally. However, interval change in BD, if the scan is a followup, will be identical on the 2 documents.
